Clene Inc. (NASDAQ: CLNN)

The QualityStocks Daily Newsletter would like to spotlight Clene Inc. (NASDAQ: CLNN).

Clene recently reported new results from the open-label, long-term extension ("LTE") of the VISIONARY-MS trial, involving participants with stable relapsing Multiple Sclerosis ("MS") through week 144 (over 2.75 years) after the initial randomization

Results from the 48-week double-blind period showed statistically significant improvements in vision (primary endpoint), as well as a combined improvement in cognition, walking speed, upper extremity function, and vision (secondary endpoint) with CNM-Au8 treatment, with further significant improvements in both vision and cognition extending throughout the 96-week LTE

One of the trial's key clinical advisors hailed the results as robust and consistent, describing the observed long-term clinical improvements as unprecedented

Data from both the double-blind trial period and the LTE build a strong case for pursuing CNM-Au8(R) in upcoming Phase 3 studies, said Dr. Benjamin Greenberg, Head of Medicine at Clene

Clene (NASDAQ: CLNN) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, recently reported new results from the open-label long-term extension ("LTE") of the VISIONARY-MS trial (https://ibn.fm/5QSDO). This was a double-blind, placebo-controlled Phase 2 clinical trial comprised of participants with chronic optic neuropathy associated with stable relapsing Multiple Sclerosis ("RMS").

Clene (NASDAQ: CLNN) CEO Rob Etherington was the featured guest on a recent Proactive interview. According to an announcement, Etherington joined Proactive host Steve Darling to discuss recent news the company has released regarding results from its long-term, open-label extension ("LTE") of the VISIONARY-MS trial. Clene is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis ("ALS"), Parkinson's disease and multiple sclerosis ("MS"). Etherington and Darling discussed the trial, which involved gathering almost three years of research and information from participants with stable relapsing MS. Darling explained that following the conclusion of the double-blind period of the trial, participants could choose to continue with CNM-Au8(R) treatment for an additional 96 weeks.

"Etherington highlighted the key finding that long-term CNM-Au8 treatment showcased improvements in vision, as measured by low contrast visual acuity, an essential assessment of visual function in individuals living with multiple sclerosis," the company stated in the press release. "Remarkably, these improvements in vision persisted for 35 months from randomization, demonstrating the sustained efficacy of CNM-Au8 over an extended period. Moreover, the data revealed consistent and robust overall enhancements not only in vision but also in cognition among participants treated with CNM-Au8 for nearly three years from randomization. These results are particularly noteworthy for their potential to positively impact disease progression and potentially reverse established disability, representing a significant therapeutic breakthrough for patients with MS."

To view the full interview, visit https://ibn.fm/Ll9GC

To view the full press release, visit https://ibn.fm/tqodV

Clene Inc. (NASDAQ: CLNN) is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis (MS).

Its lead drug candidate is CNM-Au8®, an oral suspension developed to restore neuronal health and function by increasing energy production and utilization by driving critical cellular energy producing reactions that enable neuroprotection and remyelination to increase neuronal and glial resilience to disease-relevant stressors. CNM-Au8 is being studied in various clinical trials, including the Harvard/MGH Healey ALS Platform clinical trial for patients with ALS; RESCUE-ALS, a completed proof-of-concept clinical trial in patients with early symptomatic ALS; the REPAIR trials, completed target engagement clinical trials showing brain energy metabolite change with CNM-Au8; and a completed MS clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing MS. The company also has a nanotherapeutic platform of drug discovery.

CNM-Au8

CNM-Au8, Clene’s lead asset, is a highly concentrated aqueous suspension of catalytically active, clean-surfaced, faceted gold nanocrystals. Multiple pathogenic insults contribute to neuronal death. Mitochondrial dysfunction and NAD+ decline is a common final pathway in neurodegeneration, with NAD+ as a critical determinant of cell survival and function. CNM-Au8’s catalytic mechanisms target the energetic deficits, oxidative stress and accumulation of misfolded proteins that are common to many neurodegenerative diseases.

The unique catalytic mechanism of action of CNM-Au8 is hypothesized to act as a neuroprotective and remyelinating therapy in neurodegenerative disease states in order to: (1) drive, support and maintain beneficial metabolic and energetic cellular reactions within diseased, stressed and/or damaged cells, (2) directly catalyze the reduction of harmful, reactive oxygen species (“ROS”) and (3) promote protein homeostasis via activation of the heat shock factor-1 pathway, recognized to dampen the cytotoxicity caused by misfolded and denatured proteins, which are known to occur ubiquitously in neurodegenerative diseases.

CNM-Au8 is used in combination with other agents, has no known drug-drug interactions, and is designed to improve function and survival. The clinical effects of both function and survival were seen in its clinical ALS trials, as earlier announced.

More than 500 estimated years of collective exposure across ALS, MS, and Parkinson’s disease participants in CNM-Au8 clinical trials and Expanded Access Protocol (compassionate use) programs have been recorded without any observed safety signals.

CNM-Au8 is a federally registered trademark of Clene Inc. Clene, based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland, began in 2013.

Market Opportunity

ALS is the most prevalent adult-onset progressive motor neuron disease, affecting approximately 30,000 people in the U.S. and an estimated 500,000 people worldwide, with a life expectancy of typically three to five years. Clene estimates that global ALS treatment sales will be greater than $1 billion annually within the coming few years. Additional treatments affecting daily function and survival remain the market need.

Additionally, there are more than 2 million MS patients globally, and Clene estimates the market size to be worth more than $23 billion annually. While the MS community has been successful at limiting relapses, non-relapsing MS patients continue to clinically deteriorate even while receiving effective immunomodulatory disease-modifying therapies (“DMTs”). A critical unmet medical need remains for therapeutic interventions that protect neuronal function and myelin health independent of immunomodulation to address progression independent of relapse activity.

Management Team

Robert Etherington is President, Director and CEO of Clene. He has more than 30 years of sales, marketing and leadership experience in the pharmaceutical industry. Prior to joining Clene, he worked at Actelion Pharmaceuticals, the largest biopharma company in the European Union prior to its acquisition by Johnson & Johnson in 2017, where he led that company’s U.S. commercial operations. He began his pharmaceutical sales and marketing career at Parke-Davis, a division of Pfizer, where he rose to the position of Team Leader overseeing the drug Lipitor.

Mark Mortenson is Chief Science Officer at Clene. He is co-inventor of the technology platform developed to produce the company’s therapeutics. He is the inventor or co-inventor on 32 other U.S. patents and hundreds of corresponding international patents. He is a former chief patent counsel responsible for 5,500 U.S. and international patents and patent applications. He holds bachelor’s degrees in physics and ceramic engineering from Alfred University, a master’s degree in materials science from Penn State University and a J.D. from George Washington University.

Benjamin Greenberg, M.D., MHS, FAAN, is Head of Medical at Clene. He is an internationally recognized expert in disorders of the central nervous system. He is currently professor of neurology and Vice Chair of Clinical and Translational Research in the department of Neurology at University of Texas Southwestern Medical Center in Dallas. He holds a bachelor’s degree from Johns Hopkins, a master’s degree in molecular microbiology and immunology from the Johns Hopkins School of Public Health and graduated from Baylor College of Medicine. He served residency in neurology at The Johns Hopkins Hospital.

Morgan R. Brown is CFO at Clene. He has more than 30 years of finance and accounting experience, with 23 years at biotech, pharmaceutical and medical device companies. He has served in similar roles at Lipocine Inc., Innovus Pharmaceuticals, World Heart Corp., Lifetree Clinical Research and NPS Pharmaceuticals Inc. He previously worked at accounting firm KPMG. He is a CPA with a bachelor’s degree in accounting from Utah State University and an M.S. in business administration from the University of Utah.

Clene Inc. (NASDAQ: CLNN), closed Tuesday's trading session at $0.45, up 2.2727%, on 225,632 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.25/$1.99.

Recent News

• Clene Inc. (NASDAQ: CLNN) - InvestorNewsBreaks - Clene Inc. (NASDAQ: CLNN) CEO Discusses MS Trial Results During Latest Proactive Interview
• Clene Inc. (NASDAQ: CLNN) Reports 'Unprecedented,' Statistically Significant Long-Term Clinical Improvements for VISIONARY-MS Trial Participants with Stable Relapsing-Remitting MS
• BioMedNewsBreaks - Clene Inc.'s (NASDAQ: CLNN) CNM-Au8 Produces 'Significant and Very Promising Effect' in Parkinson's, MS Patients

FuelPositive Corp. (TSX.V: NHHH) (OTC: NHHHF)

The QualityStocks Daily Newsletter would like to spotlight FuelPositive Corp. (NHHHF).

FuelPositive (TSX.V: NHHH) (OTCQB: NHHHF), a Canadian-based, growth-stage company committed to providing commercially viable and sustainable, cradle-to-cradle, clean-energy solutions, has released a report on recent company achievements and new initiatives as well as the completion of financing. The report noted a visit from the Honorable Lawrence MacAulay, Canada's federal minister of agriculture, and two local members of parliament, the Honorable Bardish Chagger and MP Tim Louis; the trio visited FuelPositive's Northland facility and engaged directly with FuelPositive's team. The report also noted the following key items: the company remains on track to deliver its first commercial system in early spring 2024 and is offering a performance guarantee on operating costs and production output for early adopters of FuelPositive technology; the company is in the final stages of selecting public and media relations firms; the company has announced its first director of sales along with a controller, a senior purchaser, an engineer of record. and a senior electrical engineer to the team; and the company has been selected as an International Industry Innovation Leader and a "Living Lab" by the Global Nitrogen Innovation Center for Clean Energy and the Environment ("NICCEE"). In addition, the report observed that FuelPositive is focused on developing an effective method to collect carbon credits in real time while also focusing on the emission-free combustion of green ammonia; the company also secured an additional $550,000 in the final tranche of its current financing, bringing the total raised in this placement to $1,900,000.

"Our transition to revenue is imminent," said FuelPositive CEO Ian Clifford in the press release. "We've invested considerable time to reach this point and are deeply grateful for the patience and support of our stakeholders. As we defy skeptics, break new ground and establish a whole new sector, we recognize the unprecedented position we hold today. Our journey owes much to the trust and confidence of both new and long-standing investors and shareholders. We're looking forward to our upcoming successes and sharing the rewards with our shareholders."

To view the full press release, visit https://ibn.fm/yEuZc

FuelPositive Corp. (TSX.V: NHHH) (OTC: NHHHF) is a growth stage company focused on licensing, partnership and acquisition opportunities building upon various technological achievements. The company is committed to providing commercially viable and sustainable clean energy solutions, including carbon-free ammonia (NH3), for use across a broad spectrum of industries and applications.

FuelPositive is headquartered in Toronto, Canada.

Hydrogen Economy Problems and FuelPositive’s Carbon-Free Technology

The hydrogen economy is currently facing many challenges. Traditional NH3 manufacturing exists on a massive scale, but centralized facilities result in some of the world’s most concentrated CO2 emissions. In total, an estimated 200 million metric tonnes of NH3 are consumed each year, with greater than 80% utilized by the agricultural sector. NH3 is also being positioned as a viable alternative to fossil fuels.

FuelPositive’s flagship carbon-free ammonia technology provides an innovative solution to these environmental concerns. Developed by Dr. Ibrahim Dincer and his team, the company’s platform allows for the in-situ production of NH3 in an entirely sustainable manner, using only water, air and sustainable electricity.

The production of hydrogen is energy intensive, but it is just one variable hindering the growth of the hydrogen economy. Other hurdles include:

• Storage – The storage of hydrogen by compression or liquification are both cost prohibitive and unsustainable.
• Distribution – The distribution network for effective hydrogen deployment has yet to be developed, as the extreme high-pressure distribution requirements to transport hydrogen would result in enormous infrastructure costs.
• End Use – R&D on the transportation-related end use applications for hydrogen is in its infancy, but almost any vehicle on the road today can be easily converted to run on NH3 at a considerably lower cost per mile traveled when compared to traditional fossil fuels.

A key benefit of FuelPositive’s patent-pending, first-of-its-kind carbon-free NH3 technology is its flexibility. The process allows for small, medium or large-scale production of NH3 on location, minimizing or even eliminating the challenges and volatility associated with storage and transportation to end use. As such, with an appropriately sized FuelPositive system and access to renewable energy, the end use applications for the company’s platform are nearly infinite.

Manufacturing Partnership

On May 19, 2021, FuelPositive announced its selection of National Compressed Air Canada Ltd. (“NCA”) to undertake manufacturing of the company’s Phase 2 hydrogen-ammonia synthesizer commercial prototype systems for carbon-free ammonia production.

In a news release detailing the partnership, FuelPositive CEO Ian Clifford noted, “This critical milestone for FuelPositive will confirm the broad application potential for our technology and is the backbone of our Carbon-Free Hydrogen-NH3 offering. Partnering with the knowledgeable and experienced team at NCA on this commercialization project will bring our development-stage program to life.”

Global Ammonia Market Outlook

The global ammonia market was valued at $52.71 billion in 2017 and is forecast to reach $81.42 billion by 2025, growing at a CAGR of 5.59%, according to data from Fior Markets (https://ibn.fm/1OfOB).

The agricultural industry consumes more than 80% of global NH3. Smaller percentages can be attributed to the waste, water treatment, refrigerants, antiseptic, textile, mining and pharmaceutical industries.

One of the most polluting industries on the planet consists of conventional agribusinesses. These polluters are responsible for more greenhouse emissions per year than transportation. This is where FuelPositive’s technology is expected to be extremely beneficial.

Management Team

Ian Clifford is Director, CEO and Founder of FuelPositive Corp. He has over 25 years of experience in the fields of technology and marketing and has successfully led the company to global brand recognition through its unique energy solutions. Since 2006, Mr. Clifford has raised over $50 million in equity financing for FuelPositive. He also co-founded digIT Interactive, a full-service internet marketing company serving Fortune 500 clients, which he sold at the peak of the market in 2000.

Greg Gooch serves as a Director and President of FuelPositive. His multifaceted career in the electronics and finance industries has positioned him as a key advisor and funding partner to start-ups and new technology companies for over 40 years. Mr. Gooch has been involved with FuelPositive since its early days and has remained a significant supporter and consultant to the company over the years. He has a bachelor’s from McGill University and an MBA from the University of Western Ontario.

Dr. Ibrahim Dincer is a scientific advisor to FuelPositive and is recognized as a pioneer and international leader in the area of sustainable energy technologies. Along with his team, Dr. Dincer invented the modular carbon-free ammonia (NH3) production technology that FuelPositive is commercializing. His area of specialty covers various topics including ammonia, hydrogen energy and fuel cells; renewable energy systems; energy storage systems and applications; carbon capturing technologies, and integrated and hybrid energy systems He is currently managing an exemplary team of researchers in this commercialization project.

Marek Warunkiewicz is the company’s Communications & Branding Specialist. He brings more than 40 years of entrepreneurial expertise to the FuelPositive team, having held marketing, branding, advertising, project management and graphic design positions with various companies. Mr. Warunkiewicz has successfully created business-to-business marketing and advertising campaigns for a diverse group of clients ranging from high-tech to agriculture. He co-founded digIT Interactive and ZENN Motor Company alongside Ian Clifford.

Luna Clifford is the Director of Communications for FuelPositive. She has over 10 years of experience as a business owner and advisor, helping build and operate several successful start-up enterprises while managing complex stakeholder relationships. Ms. Clifford excels in strategic planning and team building, and she has completed extensive studies in the fields of communications and health care.

FuelPositive Corp. (NHHHF), closed Tuesday's trading session at $0.0399, up 0.833965%, on 914,590 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.034/$0.1161.

Recent News

• FuelPositive Corp. (TSX.V: NHHH) (OTC: NHHHF) - InvestorNewsBreaks - FuelPositive Corporation (TSX.V: NHHH) (OTCQB: NHHHF) Reports on Status of Initiatives, Financing
• InvestorNewsBreaks – FuelPositive Corporation (TSX.V: NHHH) (OTCQB: NHHHF) Joins CHFCA, Sets Completion Date for Non-Brokered Private Placement
• InvestorNewsBreaks - FuelPositive Corporation (TSX.V: NHHH) (OTCQB: NHHHF) Issues Update on 2023 Milestones, 2024 Path Forward

Correlate Energy Corp. (OTCQB: CIPI)

The QualityStocks Daily Newsletter would like to spotlight Correlate Energy Corp. (OTCQB: CIPI).

Correlate (OTCQB: CIPI), a tech-enabled development, finance and fulfillment platform for distributed energy solutions across North America, is capitalizing on the continued corporate push for financially positive decentralized energy generation. "CIPI recently announced the successful commissioning of a major solar project located in American Tire Distributors' (‘ATD') Huntersville, North Carolina-based headquarters. This follows the successful commissioning of a solar project at Continental Envelope's manufacturing plant in Geneva, Illinois, making it one of the state's largest rooftop solar facilities. In the next two decades, the ATD solar power system installed will reduce CO2 emissions by as much as 5,463 tons, the equivalent of approximately 12,442,130 miles of car travel. The company is also optimistic about the benefits beyond environmental gains, specifically ATD's ability to generate substantial cost savings by reducing reliance on traditional energy sources," a recent article reads. "The just-completed ATD solar power installation reflects Correlate's competence in its space and its growing position as an industry leader. It also shows its understanding of the market and strategic approach to carving out a significant market share. As such, it looks to have a successful 2024, building on the momentum and success gained so far."

To view the full article, visit https://ibn.fm/RiaO1

Correlate Energy Corp. (OTCQB: CIPI) is a publicly-traded company strategically positioned to capitalize on America’s unstoppable trend toward decentralized energy generation.

The energy grid in the U.S. is insufficient for the booming clean energy trend, and current infrastructure is limiting green energy distribution. Constructing the needed infrastructure to address this demand imbalance will cost billions and be far too slow, positioning decentralized systems, like those on offer from Correlate, in a key position for heightened demand.

Correlate has identified several key economic drivers powering the decentralized energy trend, including:

1. Real Cost Savings – Customer pays zero money down and gets an instant electrical price discount to current rates.
2. Massive Project Investment Funding – The International Energy Agency estimates that over one billion dollars per day will be invested in solar energy in 2023.
3. Consistent Long-Term Incentives – The Inflation Reduction Act is a game-changer, supercharging renewables with $1.2 trillion in tax credits for 10 years of market support.
4. Robust Customer Demand – Wood Mackenzie expects the U.S. solar industry to nearly triple in size over the next five years.

Correlate’s team of multi-decade experts who have worked with renowned global brands are positioning the company to make the most of this opportunity while consolidating a fragmented industry. Collectively, the team has developed, financed and deployed over $2 billion in clean energy projects to date.

Three-Pronged Strategy

Correlate is leveraging a three-pronged strategy aimed at driving shareholder value:

1. Sell – Correlate seeks to finance, develop and profitably sell localized clean energy solutions and microgrids to industrial, commercial and residential customers.
2. Retain – Correlate plans to retain ownership of some of these energy systems and thereby realize ongoing, reliable cash flow.
3. Acquire – Correlate seeks to acquire proven renewable energy companies in order to exponentially grow earnings per share for investors.

This strategy is enhanced by current investment trends. Clean energy earnings are being sought after by investors. In Q4 2022, the median EBITDA multiple for green energy companies was 12.3x, according to Finerva.

Market Outlook

Over the next decade and beyond, renewable energy growth is expected to come primarily via decentralized systems like those offered by Correlate.
The Inflation Reduction Act enacted in late August 2022 is likewise expected to drive growth for the company by providing new tax incentives that reduce costs for clients and/or elevate returns to investors.

Commercial buildings consume more than 35% of the generated electricity in the U.S. and are underperforming in energy efficiency at every level. These buildings waste energy, emit too much carbon and are too costly for owners and occupants, but retrofits are not happening at the rate or scale needed.

In today’s real estate market, portfolio property owners own most commercial buildings, yet most building efficiency work is focused on single buildings, thereby missing the distinct needs of this owner class which are very different from traditional owner-occupiers. The diverse nature of commercial buildings, combined with technology and performance uncertainty, make simple energy optimization initiatives – which could greatly reduce energy use and improve building value – financially unattractive, resulting in slow adoption rates. CIPI’s financial instruments and software breakdown this issue, known as the ‘split incentive’, unlocking the majority of the addressable market.

A key portion of Correlate’s strategy relates to consolidation of what has been a fragmented industry. By uncovering opportunities to improve efficiencies through strategic M&A activities, the company intends to enhance profitability throughout its operations.

Management Team

Todd Michaels is President and CEO of CIPI and founder of Correlate. He formerly served as Vice President for Innovation at SunEdison and Senior Director Distributed Solar at NRG Energy. He founded Correlate in 2015 and has 16 years of experience in the energy industry. He graduated from Indiana University with a B.S. in Computer Information Systems.

Channing Chen is CFO at CIPI and Correlate Inc. and brings over 16 years of experience in the solar industry as a developer, financier, and business unit leader. He has held executive management roles at Solar Power Partners (acquired by NRG Energy), where he was a founding employee, SunEdison, and NRG Energy (NYSE: NRG). Most recently, Mr. Chen was founder and Managing Partner at Breakaway Energy Partners LLC – a distributed energy financing and market-making platform. To date, Mr. Chen and his teams have raised over $1.5 billion in financing across residential, commercial, and utility scale solar and energy storage projects representing over 400 MWs. He holds a B.A. in Environmental Chemistry from the University of California at San Diego and an MBA from the University of Southern California. He is also an advisor and early-stage investor to several startup companies in the renewable energy space.

Dave Bailey is Chief Revenue Officer of Correlate Inc. With over 15 years of executive sales, supply chain management, and energy efficiency experience, he is responsible for ensuring the success of the National Commercial Sales Unit across multiple regional project teams. Mr. Bailey created and launched the Transformation Services team while at Wesco for its multibillion-dollar Distributed Energy Resource division, formerly Westinghouse. His focus was on IoT-enabled efficiency and plant floor automation-based services. Before that, he spent several years in Global Account Sales Management, with GE Supply as a Program Manager, and is a Commercial Leadership Program graduate. Mr. Bailey received his B.S. in Mechanical Engineering from the University of Kentucky.

Jed Freedlander is the company’s Chief Development Officer. He has a background in infrastructure development and investment and a strong legal, commercial and finance acumen. Mr. Freedlander has a proven track record in leading complex public-private partnership (P3) and energy transactions and is instrumental in driving Correlate’s strategic development initiatives.

Roger Baum is Executive VP Operations at Correlate. With over 20 years of experience at Core Construction, he brings to the company a wealth of knowledge and a strong track record in delivering successful commercial construction projects.

Jason Loyet is Director of Solar Energy for Correlate Inc. He is a cleantech executive with over 20 years of experience leading high growth solar energy and software start-ups. Mr. Loyet is a U.S. Department of Energy SunShot Catalyst award winner for his work building the Solar Site Design technology platform. Before joining the solar energy industry in 2005, he founded and sold two software companies in the streaming media (GlobalStreams) and newspaper publishing (MyCapture) industries. Mr. Loyet currently serves as a Member of the Board of Directors for the Tennessee Solar Energy Industry Association (TenneSEIA).

Correlate Energy Corp. (OTCQB: CIPI), closed Tuesday's trading session at $1.75, even for the day. The average volume for the last 3 months is and the stock's 52-week low/high is $0.3501/$2.35.

Recent News

• Correlate Energy Corp. (OTCQB: CIPI) - GreenEnergyBreaks - Correlate Energy Corp. (CIPI) Eyes Successful 2024 on Momentum and Achievements with Solar Projects
• Correlate Energy Corp. (CIPI) Targets Growing Reliance on Renewable Energy and the Rapidly Expanding Global Renewable Energy Market
• GreenEnergyBreaks - Correlate Energy Corp. (CIPI) Providing Clients with Best-in-Class Sustainability Solutions

Genprex Inc. (NASDAQ: GNPX)

The QualityStocks Daily Newsletter would like to spotlight Genprex Inc. (NASDAQ: GNPX).

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, will be represented at the upcoming BIO CEO & Investor Conference. The conference is scheduled for Feb. 26–27, 2024, in New York City. According to the company, CFO Ryan Confer will present at the two-day event. His presentation, which will begin at 1:30 p.m. ET on Feb. 26, will include an overview of the company's gene therapies for cancer and diabetes; Confer will also be available for in-person, one-on-one meetings with investors through the conference platform.

To view the full press release, visit https://ibn.fm/s6PKq

Genprex Inc. (GNPX) is a clinical-stage gene therapy company developing potentially life-changing technologies for cancer patients based upon a unique proprietary technology platform, including Genprex’s initial product candidate, Oncoprex™ immunogene therapy for non-small cell lung cancer (NSCLC). Genprex’s platform technologies are designed to administer cancer-fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities.

Research and Development

Genprex holds a portfolio of 30 issued and two pending patents covering its technologies and targeted molecular therapies. The company’s research and development program is focused on identifying and developing leading-edge gene therapies that can be used alone or in combination with other therapies for treatment of cancer.

Genprex’s initial product candidate is Oncoprex™, an immunogene therapy for the treatment of non-small cell lung cancer (NSCLC). Oncoprex works by interrupting cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis (or programmed cell death) in cancer cells, and modulates the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance.

Preclinical research is being conducted with the goal of developing Oncoprex to be administered with targeted therapies in other solid tumors, and with immunotherapies in NSCLC and other solid tumors. In addition, Genprex has conducted and plans to continue research into other tumor suppressor genes associated with chromosome 3p21.3, as well as other potential applications of the company’s immunogene therapy platform.

Clinical Trials

Genprex is currently conducting the second phase of a phase I/II clinical trial at the University of Texas MD Anderson Cancer Center in Houston. The company plans to expand its clinical program by adding a new clinical study evaluating Oncoprex™ in combination with a checkpoint inhibitor for treatment of Stage IV or recurrent NSCLC. In research presented at the 2017 Annual Meeting of the American Association of Cancer Research in Washington, D.C., Genprex’s collaborators showed that TUSC2 in combination with PD-1 checkpoint inhibition has a significantly greater anti-tumor effect in lung cancer than either agent alone. The research also shows that TUSC2 in combination with PD-1 blockade has synergistic activity in upregulating natural killer (NK) cells, correlating with prolonged survival in mice.

TUSC2 (Tumor Suppressor Candidate 2) is a tumor suppressor gene that is absent or deficient in cancer cells of many different cancer types.

The Market

Genprex technologies seek to bridge a critical gap by combining with targeted therapies and immunotherapies to provide treatments to large patient populations who would otherwise not be candidates for those therapies or who have become resistant to them. Genprex technologies are being developed to overcome genomic limitations which are inherent in targeted therapies and immunotherapies in order to provide new treatment solutions to large cancer populations, such as those with lung cancer.

Each year, more people die of lung cancer than of colon, breast and prostate cancers combined. NSCLC is the most common type of lung cancer, accounting for about 85 percent of all lung cancers, according to the American Cancer Society (“ACS”). Despite radical advances in drug development and novel therapeutic standards, survival for late stage lung cancer has not improved significantly in the past 25 years.

Senior Management

Chairman and Chief Executive Officer J. Rodney Varner, JD, is a co-founder of Genprex and has served in these roles since August 2012. He has more than 35 years of legal experience with large and small law firms and as outside general counsel of a Nasdaq-listed company. Varner has served as counsel in company formation, mergers and acquisitions, capital raising, other business transactions, protection of trade secrets and other intellectual property, real estate, and business litigation. He is a member of the State Bar of Texas and has been admitted to practice before the U.S. Court of Appeals for the Fifth Court and the U.S. Tax Court.

Julien L. Pham, M.D., MPH, is president and chief operating officer of Genprex. In March 2013, Dr. Pham co-founded RubiconMD, a healthcare IT company that connects primary care providers to specialists for additional guidance and opinions on medical cases and served as its chief medical officer. He has served on the faculty at Harvard Medical School’s Brigham and Women’s Hospital and is a board-certified internal medicine doctor and nephrologist.

Ryan M. Confer, MS, has served as Genprex chief financial officer since September 2016. Confer has more than 10 years of executive experience in planning, launching, developing, and growing emerging technology companies and has served in the chief operating and chief financial roles for non-profit and for-profit entities since 2008. Confer has also served as an international business development consultant for the University of Texas at Austin’s IC2 Institute, where he focused on evaluating the commercialization potential of nascent technologies in domestic and international markets applicable to technology incubator programs associated with the University. Confer holds a BS in finance and legal studies from Bloomsburg University of Pennsylvania and an MS in technology commercialization from the McCombs School of Business at the University of Texas at Austin.

Jan Stevens, RN, is vice president of Clinical Operations. Stevens has nearly 20 years of comprehensive clinical operations experience in the biopharma industry and a specialization in early-to-late stage oncology companies. Stevens joined the company to help support the various clinical development programs for Oncoprex™.

Genprex Inc. (NASDAQ: GNPX), closed Tuesday's trading session at $6, off by 10.4478%, on 137,152 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $5.15/$74.80.

Recent News

• Genprex Inc. (NASDAQ: GNPX) - InvestorNewsBreaks - Genprex Inc. (NASDAQ: GNPX) Announces Participation at This Month's BIO CEO & Investor Conference
• InvestorNewsBreaks - Genprex Inc. (NASDAQ: GNPX) Phase2a Expansion of Acclaim-1 Clinical Study Enrolls, Doses First Patient
• Genprex Inc. (NASDAQ: GNPX) Granted Orphan Drug Designation in Small Cell Lung Cancer by FDA, Presented Data at Two October Events Focused on Lung Cancer

Turbo Energy S.A. (NASDAQ: TURB)

The QualityStocks Daily Newsletter would like to spotlight Turbo Energy S.A. (NASDAQ: TURB).

Turbo Energy announces strategic partnership with Solar360, a joint venture between two Spanish heavyweights, Repsol and Telefónica España

Turbo Energy will be the technology provider while Solar360 will be tasked with marketing energy services and installing Turbo Energy's smart batteries in residential, commercial, and industrial locations in Spain

The companies are optimistic that this partnership will revolutionize the photovoltaic market in 2024, delivering substantial value to both parties and to consumers

Turbo Energy (NASDAQ: TURB), a photovoltaic energy storage innovator, has started the new year on a high note with a strategic alliance announcement. The company has forged a collaboration with Solar360, a joint venture of Repsol and Telefónica España, signaling a promising beginning for Turbo Energy in 2024. In this partnership, Turbo Energy will supply technology while Solar360 will take on the responsibility of promoting energy services by installing Turbo Energy's smart batteries in residential, commercial, and industrial locations across Spain (https://ibn.fm/SFkkc).

Turbo Energy S.A. (NASDAQ: TURB) designs, develops and distributes equipment for the generation, management and storage of photovoltaic energy in Spain, Europe and internationally.

Turbo Energy’s products include lithium-ion batteries and inverters. Additionally, the company recently launched its flagship product, the Sunbox, an all-in-one device that integrates most of the equipment required for a residential photovoltaic installation. The Sunbox is powered by AI and features a software system that monitors the generation, use and management of photovoltaic energy by analyzing large amounts of data related to energy generation, consumption, market prices and weather forecasts. This AI system optimizes battery usage, reducing electricity bills and providing peak-use reduction and uninterruptible power supply functions.

Turbo Energy currently sells its photovoltaic energy equipment primarily through distributors for residential consumers in Spain, but it possesses the expertise and international perspective to expand its product portfolio into industrial and commercial scale and markets, as well as advancing the internationalization process it has already started. The company plans to expand into the industrial photovoltaic sector with its new Sunbox, launched in 2023, in higher power and capacity variants. Its goal is to become a significant player in this sector and contribute to the growth of renewable energy solutions.

The company was incorporated in 2013 and is based in Valencia, Spain. It operates as a subsidiary of Umbrella Solar Investment S.A.

Products

Lithium-Ion Batteries

Turbo Energy is one of the leading companies that introduced lithium-ion batteries for photovoltaic energy storage in Spain. Primarily for the home energy storage market, the company’s batteries have capacities from 2.24 kWh to 5.1 kWh in 24 and 48 volts. In addition, its 48V / 5.1 kWh units are available in a dual battery system.

Inverters

The inverter converts the direct current produced by the photovoltaic panels into alternating current that can be used by household appliances. It also regulates battery charging and discharging based on energy needs and optimizes utilization of generated renewable energy. Turbo Energy currently offers multiple models that cover most household installations.

All-in-One Sunbox

This product incorporates inverters, batteries and the rest of the components necessary to operate and protect the photovoltaic installation. This saves installation cost and assembly and configuration time while preventing errors. Notably, the latest Sunbox models also offer an EV charging option.

Software System

In communication with the inverter, the company’s software monitors energy flows between the photovoltaic panels, household consumption, storage and an optional electric vehicle charging station. The software allows users to customize an automatic backup mode based on weather forecasts, or manually select which part of the battery will be reserved for possible power outages. It also allows the battery to be used in a peak shaving mode, which leverages AI to trigger battery power when grid energy is most expensive, effectively reducing the amount of high-cost power drawn from the grid.

Market Opportunity

According to a report by Fortune Business Insights, a global research and reporting firm, the solar energy storage battery market was estimated to be worth $3.33 billion in 2022 and is projected to reach a value of more than $20 billion by 2030, marking a CAGR of 24.2% over the forecast period.

These batteries are crucial components of renewable energy systems, allowing for the storage of excess electricity generated by solar panels, so it can be used during times of no or low sunlight. By storing energy and supplying it when needed, these batteries reduce reliance on the power grid and maximize self-consumption while helping users avoid peak electricity rates. They also contribute to the transition toward a cleaner and more sustainable energy future by enabling residential consumers and businesses to use solar power even when the sun is not shining.

Management Team

Enrique Selva Bellvís is the CEO and founder of the Umbrella Group. In addition, he serves as vice-president of the Valencian Association of Energy Sector Companies industry group. Before his career in the solar energy sector, he was the founder and CEO of Innova Ingenieros Consultores. He holds a degree in industrial engineering with a specialization in energy from the Polytechnic University of Valencia and completed the Management Development Programme at the IESE Business School.

Mariano Soria is the Chief Innovation Officer for the Umbrella Group and serves as General Manager of Turbo Energy. He was CEO of Punt Moble XXI S.L. and continues to serve on that company’s board. Before that, he was the General Manager of REJMAR S.A., a land development company. He received his degree in industrial engineering and industrial organization from the Polytechnic University of Valencia, and his MBA from the European University of Madrid.

Alejandro Moragues is CFO of Turbo Energy. Previously, he held the position of Senior Corporate Auditor for U.S. company Euronet Worldwide Inc. and was an external auditor for PricewaterhouseCoopers. He holds a bachelor’s degree in business administration and management from the Polytechnic University of Valencia.

Manuel Cercos is Chief Commercial Officer at Turbo Energy. Previously, he held positions at Técnicas Aplicadas en Baterías S.L., where he served as Sales Director and Sales Manager. Before that, he worked as a Sales Technician at DAISA.

Turbo Energy S.A. (NASDAQ: TURB), closed Tuesday's trading session at $1.0101, off by 0.970588%, on 11,930 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.855/$7.90.

Recent News

• Turbo Energy S.A. (NASDAQ: TURB) - Turbo Energy's (NASDAQ: TURB) Sunbox Selected to Power Up Solar360's Capabilities Aiming to Transform Spain's Photovoltaic Landscape in 2024
• GreenEnergyBreaks - Turbo Energy S.A.'s (NASDAQ: TURB) Products Contributing to Sustainable Reduction of Energy Costs for Thousands of Homes and Businesses
• Turbo Energy (NASDAQ: TURB) Seeks to Help Facilitate Global Decarbonization Goals

Longeveron Inc. (NASDAQ: LGVN)

The QualityStocks Daily Newsletter would like to spotlight Longeveron Inc. (NASDAQ: LGVN) .

Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, was spotlighted in a recent H.C. Wainwright & Co. research report after the Company's announcement about receiving a Notice of Allowance from the U.S. Patent and Trademark Office ("USPTO") for a patent application related to the use of Lomecel-B(TM) in Aging-related Frailty sufferers receiving vaccines for conditions such as COVID-19 and influenza.

"In our view, the notice of patent allowance further bolsters the Lomecel-B(TM) intellectual property (‘IP') estate and may serve as a life-cycle management (‘LCM') tool should additional evidence support the agent's value in treating frailty patients," wrote Boobalan Pachaiyappan, Ph.D, in the report. "Investors should note that we do not currently ascribe any value to the frailty program; however, positive updates may constitute upside to our forecasts. In the wake of this update, we reiterate our Buy rating and 12-month target of $6 per share."

In the press release announcing the Notice of Allowance last week, Joshua M. Hare, M.D., FACC, FAHA, Co-Founder and Chief Scientific Officer and Chairman of Longeveron, stated, "these newly allowed claims extend our patent estate to include the use of Lomecel-B(TM) in conjunction with or after patients receive vaccines to enhance vaccine immune response. We believe this use for Lomecel-B(TM) and the broader potential it holds for patients in our current Aging-related Frailty and Alzheimer's disease trials reflects the broader potential of Lomecel-B(TM)."

To learn more about H.C. Wainwright & Co. research and request access to the full report,, visit https://hcwco.com/services/research/

Longeveron Inc. (NASDAQ: LGVN) is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. The Company’s research and therapies are aimed at improving the outcome of infants born with a life-threatening heart condition, as well as improving the healthspan for the aging population – the number of years a person is expected to live in relatively good health, free of chronic disease and disabilities of aging, with function and ability to perform activities of daily living.

Longeveron is involved in clinical trials in the following indications: Hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, and Aging-related Frailty.

The Company’s philosophy revolves around the idea that regenerative medicine may hold the potential to improve certain rare medical conditions and contribute to healthy aging. While there has been a remarkable rise in life expectancy over the last century due to medical and public health advancements, this increase in longevity has not been paralleled by the number of years a person is expected to live in relatively good health, free of chronic disease and disabilities of aging.

Longeveron’s lead investigational product is Lomecel-B™, an allogeneic Medicinal Signaling Cell therapy product isolated from the bone marrow of young, healthy adult donors. As humans age, they experience a decrease in immune system function, a decline in blood vessel functioning, chronic inflammation, and other issues. Clinical data has suggested that Lomecel-B™ may address these conditions through multiple mechanisms of action (MOA) that simultaneously target key aging-related processes.

The Company is headquartered in Miami, Florida.

Lomecel-B™

Lomecel-B™ is being evaluated in multiple clinical trials for aging-related chronic diseases and other life-threatening conditions under U.S. FDA-approved Investigational New Drug applications. Lomecel-B™ has multiple potential mechanisms of action encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas.

The drug is made from special living cells called Medicinal Signaling Cells (MSCs) that are isolated from fresh bone marrow tissue that has been donated by adult donors aged 18 to 45. Once the MSCs have been isolated from the fresh bone marrow through a careful selection process, the cells are culture-expanded (allowed to replicate under controlled laboratory conditions) into the billions using specialized techniques and processes. After a specific number of expansion cycles, called “passages,” the cells are harvested, separated into specific doses (e.g., 50 million cells), and cryopreserved until future use.

These cells have been shown to have characteristics that allow them to be transplanted from a donor to host without triggering a harmful immune response in the recipient, and they can be administered on an outpatient basis in as little as 40 minutes after thawing. Because of these characteristics, Lomecel-B™ is considered an “off-the-shelf” product.

In some trials, such as for Alzheimer’s disease and Aging-related Frailty, Lomecel-B™ is administered via peripheral intravenous infusion, while, in the Company’s HLHS trial, Lomecel-B™ is administered via direct injection into the heart tissue.

Market Opportunity

Longeveron estimates the potential market size for Lomecel-B™ in the treatment of HLHS to be up to $1 billion annually, globally.

U.S. patients suffering from Aging-related Frailty are estimated using U.S. Census Bureau statistics to be approximately 8.1 million. That population potentially represents a market for Lomecel-B™ of between $4 billion and $8 billion globally per year, according to Company estimates.

Additionally, the Alzheimer’s Association puts the number of Americans with that disease at 5.1 million, highlighting another potentially addressable market for Lomecel-B™, that’s worth $5 billion to $10 billion annually.

Management Team

Wa’el Hashad is CEO of Longeveron. He has more than 35 years of experience in the pharmaceutical and biotech industries. He has launched several successful brands in the U.S. and worldwide markets. Prior to joining Longeveron, he was president and CEO of Avanir Pharmaceuticals. Before Avanir, he was the chief commercial officer of Seres Therapeutics. He also has held senior leadership positions at Amgen, Boehringer Ingelheim, and Eli Lilly and Company. He holds a bachelor’s degree in pharmacy from Cairo University and an MBA from the University of Akron.

Joshua M. Hare, M.D., FACC, FAHA, is Co-Founder, Chief Science Officer and Chairman of Longeveron. He is a double board-certified cardiologist and is the founding director of the Interdisciplinary Stem Cell Institute at the University of Miami’s Miller School of Medicine. He is a recipient of the Paul Beeson Physician Faculty Scholar in Aging Research Award and is an elected member of the American Association of Physicians and The American Society for Clinical Investigation. He is also an elected Fellow of the American Heart Association. He received a bachelor’s degree from the University of Pennsylvania and his M.D. from The Johns Hopkins University School of Medicine.

Lisa Locklear is CFO at Longeveron. She previously served as the senior vice president and CFO for Avanir Pharmaceuticals. Prior to Avanir, she held senior financial roles at GSN Games, CoreLogic, Ingram Micro, the Walt Disney Company, and Price Waterhouse, with assignments in Paris and London. She holds a bachelor’s degree in plant science from the University of California, Davis, and an MBA from the University of California, Irvine. She is a licensed CPA (inactive) and is a member of the American Institute of Certified Public Accountants, the California Society of CPAs, and Financial Executives International.

Dr. Nataliya Agafonova, M.D., is the Chief Medical Officer at Longeveron. She previously served as clinical development lead, senior medical director, and product development chair at Otsuka Pharmaceuticals. Before that, she was the clinical development lead and senior medical director at Bristol-Myers Squibb. She previously held senior leadership positions at Ardea Bioscience, Biogen, Amgen, and Genzyme Corporation. She earned an M.D. from the Ukrainian National Medical University and completed her internal medicine residency at Kharkov State University Hospital in Ukraine.

Certain statements in this corporate profile that are not historical facts are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, which reflect management’s current expectations, assumptions, and estimates of future operations, performance and economic conditions, and involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the statements made herein. Forward-looking statements are generally identifiable by the use of forward-looking terminology such as “believe,” “expects,” “may,” “looks to,” “will,” “should,” “plan,” “intend,” “on condition,” “target,” “see,” “potential,” “estimates,” “preliminary,” or “anticipates” or the negative thereof or comparable terminology, or by discussion of strategy or goals or other future events, circumstances, or effects. Factors that could cause actual results to differ materially from those expressed or implied in any forward-looking statements in this release include, but are not limited to, statements regarding the offer and sale of securities, the terms of the offering, about the ability of Longeveron’s clinical trials to demonstrate safety and efficacy of the Company’s product candidates, and other positive results; the timing and focus of the Company’s ongoing and future preclinical studies and clinical trials and the reporting of data from those studies and trials; the size of the market opportunity for the Company’s product candidates, including its estimates of the number of patients who suffer from the diseases being targeted; the success of competing therapies that are or may become available; the beneficial characteristics, safety, efficacy and therapeutic effects of the Company’s product candidates; the Company’s ability to obtain and maintain regulatory approval of its product candidates in the U.S., Japan and other jurisdictions; the Company’s plans relating to the further development of its product candidates, including additional disease states or indications it may pursue; the Company’s plans and ability to obtain or protect intellectual property rights, including extensions of existing patent terms where available and its ability to avoid infringing the intellectual property rights of others; the need to hire additional personnel and the Company’s ability to attract and retain such personnel; the Company’s estimates regarding expenses, future revenue, capital requirements and needs for additional financing; the Company’s need to raise additional capital, and the difficulties it may face in obtaining access to capital, and the dilutive impact it may have on its investors; the Company’s financial performance and ability to continue as a going concern, and the period over which it estimates its existing cash and cash equivalents will be sufficient to fund its future operating expenses and capital expenditure requirements. Additionally, Longeveron makes no assurance that any public offering of its securities as described herein will occur on the timelines, in the manner or on the terms anticipated due to numerous factors. Further information relating to factors that may impact the Company’s results and forward-looking statements are disclosed in the Company’s filings with the Securities and Exchange Commission, including Longeveron’s Annual Report on Form 10-K for the year ended December 31, 2022, filed with the Securities and Exchange Commission on March 14, 2023 and its Quarterly Report on Form 10-Q for the second quarter of 2023 filed with the SEC on August 11, 2023. The forward-looking statements contained in this corporate profile are made as of the date of this corporate profile, and the Company disclaims any intention or obligation, other than imposed by law, to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Investor Contact
Mike Moyer
LifeSci Advisors
Tel: 617-308-4306
Email: mmoyer@lifesciadvisors.com

Date prepared: August 31, 2023

Longeveron Inc. (NASDAQ: LGVN), closed Tuesday's trading session at $0.53, off by 0.581504%, on 116,849 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.4175/$4.40.

Recent News

• Longeveron Inc. (NASDAQ: LGVN) - InvestorNewsBreaks - H.C. Wainwright & Co. Reiterates 'Buy' Rating, $6 PT on Longeveron (NASDAQ: LGVN)
• InvestorNewsBreaks - Longeveron Inc. (NASDAQ: LGVN) Granted US Patent Allowance for Key Technology Behind Lead Investigation Product
• Scientists Discover Alzheimer's Can Be Categorized into Five Subtypes

NextPlat Corp. (NASDAQ: NXPL) (NASDAQ: NXPLW)

The QualityStocks Daily Newsletter would like to spotlight NextPlat Corp. (NASDAQ: NXPL) (NASDAQ: NXPLW).

According to a 2021 study by McKinsey & Company, 71% of customers expect companies to deliver personalized experiences while 78% choose to pay higher prices for personalized services or custom services. The study revealed that companies with great personalization earn roughly 40% more revenue from personalization-related activities compared to companies with average personalization. The research also found that 75% of customers recently tried a new shopping behavior, indicating that it is getting increasingly hard for brands to gain and retain customer loyalty. Personalization has become very important to customers who, on average, expect some degree of personalization in their interactions with businesses and become frustrated when there is little personalization. With artificial intelligence (AI) and machine learning making significant advancements in recent years, many businesses are using the technology to boost their e-commerce personalization. The key to e-commerce personalization is understanding customers and offering them experiences that are tailored to their needs. This ensures they have enjoyable experiences every time they visit an online store, which increases their chances of becoming repeat customers. e-Commerce platforms that focus on the healthcare segment, such as NextPlat Corp. (NASDAQ: NXPL) (NASDAQ: NXPLW), have to be more specific in their personalization efforts because each patient is unique and requires highly targeted product recommendations, marketing content and other communication.

NextPlat Corp. (NASDAQ: NXPL) (NASDAQ: NXPLW), a next generation e-commerce platform, was created with vision and purpose to capitalize on high growth sectors and global markets. The company collaborates with businesses – large and small – to simplify and accelerate online commerce and uniquely enables customers and partners to optimize their e-commerce reach, presence and revenue. NextPlat recently launched a new e-commerce development program to provide American businesses with easy access to the massive Chinese consumer market.

Current Initiatives

NextPlat provides cutting edge technology in an advanced e-commerce ecosystem. The company is actively expanding its global network of online storefronts serving thousands of consumers, enterprises and governments. The company also has developed a next generation platform built for Web3 that enables the creation and sale of digital assets, as well as optimizing e-commerce transactions and business building activities. The company’s current initiatives include:

• E-Commerce Development Program – In April 2023, NextPlat announced it had entered into a merchant sourcing agreement with Alibaba.com Singapore E-Commerce Private Limited (“Alibaba”) and its Tmall Global e-commerce platform whereby the two companies will collaborate to increase the sale of products produced and sold by American companies to the multi-trillion-dollar Chinese consumer market. Alibaba’s Tmall Global e-commerce platform will provide NextPlat customers a turn-key solution through which products can be sold to the Chinese consumer market. The launch of the Florida E-Commerce Development Program is the first in a series of new NextPlat programs designed to assist U.S. businesses in expanding their online sales capabilities to reach new international customers in the Chinese market. NextPlat intends to rapidly expand this unique e-commerce development opportunity to businesses throughout the United States and all of North America, as well as Central and South America. The new development program features NextPlat’s turnkey global e-commerce solution for customers and leverages NextPlat’s relationships with key partners, including Tmall Global, China’s largest cross-border B2C online marketplace.
• Progressive Care Inc. – In August 2022, NextPlat completed a strategic $7 million investment in Progressive Care Inc. (OTCQB: RXMD), a personalized health care services and technology company. In a news release announcing the investment, NextPlat CEO Charles M. Fernandez noted that the company is “committed to harnessing the power of digital technologies to capitalize on the ongoing digital transformation of Progressive Care and the entire health care industry.” NextPlat intends to accelerate Progressive Care’s digital health care transformation with the launch of a new e-commerce platform for health care products later this year.
• NextPlat NFT Platform – Building on its existing e-commerce initiatives, NextPlat is working to bridge the gap between tangible and digital e-commerce marketplaces by incorporating burgeoning Web3 technologies. The company intends to launch a fully integrated NFT platform in the coming months that will enable brands to create, manage and authenticate digital assets while serving as a new source of revenue for NextPlat. Through this model, the company will receive a portion of the revenue generated from branded NFT drops, as well as subsequent secondary market transactions.
• Global Telesat Communications and Orbital SatCom Corp. – Targeting both domestic and international markets, NextPlat’s subsidiaries leverage partnerships with major e-commerce platforms such as Amazon, Alibaba, eBay and Walmart to serve a growing base that includes more than 50,000 corporate, governmental and individual customers. In total, the brands market more than 10,000 individual products, with a focus on satellite-based connectivity solutions. In addition to exploring accretive M&A opportunities, NextPlat aims to diversify its range of products and broaden its geographic footprint moving forward in an effort to better capitalize on the tremendous growth potential in the United States, Europe and Asia.

“Our goal for 2023 and beyond is to leverage our improved operational capabilities and enhanced leadership team as we expand our offerings in communications and connectivity into the high-growth health care market where we intend to launch an array of innovative new offerings,” Fernandez said in a March 2023 news release detailing the company’s record top-line performance. “Although there remain supply chain headwinds and the challenge of global inflation, we are confident that we have the right combination of market-tested expertise, technology and partnerships that will enable us to bring the power of e-commerce to more customers, brands and industries in the United States and abroad.”

Market Opportunity

The rapid growth of e-commerce over the last decade is expected to continue for the foreseeable future. According to data published by Forbes, roughly 20.8% of all retail purchases are expected to take place online in 2023, accounting for total sales of $6.31 trillion worldwide. It total, e-commerce sales are expected to grow by 10.4% YoY in 2023, accounting for a whopping 24% of all retail purchases by 2026.

For NextPlat, existing partnerships in the industry could be key to capitalizing on this growth. The Forbes report indicates that Amazon accounts for roughly 38.7% of e-commerce sales, while sites like Walmart, eBay and Alibaba round out the list of most visited e-commerce websites. Alibaba is especially interesting due to NextPlat’s recent strategic merchant sourcing agreement with Tmall Global. The Chinese market is “mammoth,” as a recent Alizila report noted. The country’s annual online retail sales of physical goods have nearly doubled in the last five years, reaching approximately 13.8 trillion yuan in 2022, which is nearly $2 trillion USD.

The health care portion of the e-commerce market is generating particularly bullish forecasts, bolstered by the continued adoption of the 340B Drug Pricing Program in the U.S., which requires most drug manufacturers to provide outpatient drugs to covered entities at significantly reduced prices. Industry reports suggest that the global health care e-commerce market will expand at a compound annual growth rate of 16.8% from 2022 to 2030, climbing to a value of more than $1.37 trillion by the end of the forecast period.

Management Team

Charles M. Fernandez, CEO, Executive Chairman and Director of NextPlat, has over three decades of experience in identifying profitable start-up and dislocation opportunities, building significant value and executing exit strategies as an entrepreneur and global investor. Successful across multiple sectors, Fortune Magazine actually labeled Fernandez ‘a restructuring whiz’. As President of Fairholme Capital Management, which he joined in 2008, Mr. Fernandez co-managed all three Fairholme funds and brought in a $2 billion gain for shareholders. Throughout his impressive career, he has participated in more than 100 significant mergers, acquisitions and product development projects across multiple industries. Mr. Fernandez was the founder, Chairman and CEO of eApeiron Solutions LLC, a brand protection and e-commerce company in partnership with Alibaba (NYSE: BABA) and Eastman Kodak (NYSE: KODK), which was successfully sold to Smartrac, a unit of Avery Dennison Corp. (NYSE: AVY).

Rodney Barreto is Chairman and CEO of the Barreto Group and Director of Nextplat. Mr. Barreto’s business career spans over 35 years, including his role at the Barreto Group and, earlier, as the founding partner of Floridian Partners LLC, a corporate and public affairs consulting firm recognized by policy makers as one of the top in its industry in Florida. He chaired the Super Bowl Host Committee in 2007, 2010 and 2020, helping to raise more than $100 million for the success of Miami Super Bowls. As a philanthropist and conservationist, Mr. Barreto is also a three-time appointee to the Florida Fish and Wildlife Conservation Commission, where he has served for over 10 years including holding the title of Chairman eight times. He has twice chaired the Annual U.S. Conference of Mayors, was Chairman of the 1999 Breeder’s Cup Championship held in South Florida and was the Chairman of the 1999 Sister Cities International Convention in Miami. Currently, Mr. Barreto is the Membership Chairman of the Florida Council of 100, and a member of the Boards of Fairchild Tropical Botanic Garden, the Baptist Health South Florida Giving Society, the Bonefish and Tarpon Trust, the Guy Harvey Ocean Foundation, and a member of Miami Dade County Schools Superintendent Carvalho’s Business Advisory Council. Prior to his career in public affairs and real estate, Mr. Barreto was a City of Miami police officer and is a member of the Florida Highway Patrol Advisory Council.

NextPlat Corp. (NXPL), closed Tuesday's trading session at $1.54, off by 1.9108%, on 12,207 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $1.23/$4.26.

Recent News

• NextPlat Corp. (NASDAQ: NXPL) (NASDAQ: NXPLW) - How AI Could Revolutionize Personalization in e-Commerce
• InvestorNewsBreaks - NextPlat Corp. (NASDAQ: NXPL) Announces Upcoming Launch and Expansion of OPKO Health-Branded Storefront
• SEO Tips to Enhance Online Visibility of eCommerce Retailers

Lexaria Bioscience Corp. (NASDAQ: LEXX)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (NASDAQ: LEXX).

Lexaria Bioscience Corp. (NASDAQ: LEXX) is a global innovator in drug delivery platforms. The company’s patented technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules. DehydraTECH promotes fast-acting, less expensive and more effective oral drug delivery and has been thoroughly evaluated through in vivo, in vitro and human clinical testing.

DehydraTECH is covered by 21 issued and more than 50 pending patents in over 40 countries around the world. Lexaria’s first patent was issued by the U.S. Patent and Trademark Office in October 2016 (US 9,474,725 B1), providing 20 years of patent protection expiring June 2034. Multiple patents have been awarded since then and are expected in the future.

Lexaria has also collaborated with the National Research Council (NRC), the Canadian government’s premier research and technology organization. The company has been granted patent protection for specific delivery of nicotine, vitamins, NSAIDs, antiviral drugs, cannabinoids and more.

Lexaria began developing DehydraTECH in 2014 and has since continued to strengthen and broaden the technology. The company has no plans to create or sell Lexaria-branded products containing controlled substances. Instead, Lexaria licenses its technology to other companies around the world to offer consumers the best possible performance across an array of ingestible product formats.

The company’s technology is best thought of as an additional layer that providers of consumer supplements, prescription and non-prescription drugs, nicotine and CBD products can utilize to improve the effectiveness of their own existing or planned new offerings. Lexaria has licensed DehydraTECH to multiple companies, including a world-leading tobacco producer for the research and development of smokeless, oral-based nicotine products, and for use in industries that produce cannabinoid beverages, edibles and oral products.

DehydraTECH is suitable for use with a wide range of product formats including pharmaceuticals, nutraceuticals, consumer packaged goods and over-the-counter capsules, pills, tablets and oral suspensions.

DehydraTECH Technology

Lexaria’s DehydraTECH is designed specifically for formulating and delivering lipophilic (fat-soluble) drugs and active ingredients. DehydraTECH increases their effectiveness and improves the way active pharmaceutical ingredients enter the bloodstream. The major benefits to a subject ingesting a DehydraTECH-enabled drug or consumer product can be summarized by the following:

• Speeds up delivery – the effects of the product are felt by the subject in just minutes.
• Increases bioavailability – the technology is much more effective at delivering a drug or product into the bloodstream.
• Increases brain absorption – animal testing suggests significant improvement in the quantity of drug delivered across the blood-brain barrier.
• Improves drug potency – more of the ingested product is made available to the body, so lower doses are required to achieve the desired effect.
• Reduces drug administration cost – lower doses mean lower overall drug costs.
• Masks unwanted taste – the technology eliminates or reduces the need for sweeteners.

Lexaria has demonstrated in animal studies a propensity for DehydraTECH technology to elevate the quantity of drug delivered across the blood-brain barrier by as much as 1,900 percent, initiating additional new patent applications and opening possibilities for improved drug delivery.

Since 2016, DehydraTECH has repeatedly demonstrated, with cannabinoids and nicotine, the ability to increase bio-absorption by up to five to 10 times, reduce time of onset from one to two hours to just minutes, and mask unwanted tastes. The technology is to be further evaluated for additional orally administered bioactive molecules, including antivirals, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs) and nicotine.

Market Outlook

Lexaria’s ongoing research and development efforts are mainly focused on development of product candidates across several key segments:

• Oral Cannabinoids – a market estimated to be worth $18.4 billion in 2021 and expected to reach $46.2 billion by 2025.
• Antivirals – an estimated $52.1 billion market in 2021 that’s expected to grow to $66.7 billion by 2025.
• Oral Mucosal Nicotine – smokeless tobacco products, a $13.6 billion market in 2018, is forecast to grow at 7.2 percent annually through 2025.
• Human Hormones – estrogen and testosterone replacement therapies represented a $21.9 billion market in 2019, with a forecast CAGR of 7.7 percent through 2027.
• Ibuprofen and Naproxen – NSAID sales totaled $15.6 billion globally in 2019 and are projected to reach $24.4 billion by 2027.
• Vitamin D3 – the global market size was $1.1 billion in 2021, growing at 7 percent per year and expected to reach $1.7 billion in 2026.

Management Team

Chris Bunka is Chairman and CEO of Lexaria Bioscience Corp. He is a serial entrepreneur who has been involved in several private and public companies since the late 1980s. He has extensive experience in the capital markets, corporate governance, mergers and acquisitions, as well as corporate finance. He is named as an inventor on multiple patent innovations.

John Docherty, M.Sc., is the President of Lexaria. He is a pharmacologist and toxicologist, and a specialist in the development of drug delivery technologies. He is the former president and COO of Helix BioPharma Corp. (TSX: HBP). He is named as an inventor on multiple issued and pending patents.

Greg Downey is Lexaria’s CFO. He has more than 35 years of diverse financial experience in the mining, oil and gas, manufacturing, and construction industries, and in the public sector. He served for eight years as CFO for several public companies and has provided business advisory and financial accounting services to many large organizations.

Gregg Smith is a strategic advisor to Lexaria. He is a founder and private investor with Evolution VC Partners. He is a member of the Sand Hill Angels and held previous investment banking roles with Cowen and Company and Bank of America Merrill Lynch.

Dr. Philip Ainslie serves as a scientific and medical advisor to Lexaria. He is co-director for the Centre for Heart, Lung and Vascular Health, Canada. He is also Research Chair in Cerebrovascular Physiology and Professor at the School of Health and Exercise Sciences, Faculty of Health and Social Development at the University of British Columbia.

Lexaria Bioscience Corp. (LEXX), closed Tuesday's trading session at $1.94, up 13.4503%, on 549,503 volume. The average volume for the last 3 months is 127,218 and the stock's 52-week low/high is $0.6488/$3.5953.

Recent News

• Lexaria Bioscience Corp. (NASDAQ: LEXX) - Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces 2024 GLP-1 Human and Animal Studies Roadmap
• InvestorNewsBreaks - Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Submission of IND for Planned Phase 1b Hypertension Trial
• Lexaria Bioscience Corp. (NASDAQ: LEXX) To Hit High Ground in Q2 and Q3 2024 with Animal and Human GLP-1 Study Programs

Fathom Nickel Inc. (CSE: FNI) (FSE: 6Q5) (OTCQB: FNICF)

The QualityStocks Daily Newsletter would like to spotlightFathom Nickel Inc. (CSE: FNI) (FSE: 6Q5) (OTCQB: FNICF).

Fathom Nickel Inc. (CSE: FNI) (FSE: 6Q5) (OTCQB: FNICF) is a Canadian natural resource development and exploration company that targets high-grade nickel sulfide discoveries for use in the rapidly growing global electric vehicle (EV) market. The company has a portfolio of two high-quality exploration projects located in the prolific Trans Hudson Corridor in Saskatchewan.

Led by a management team with more than 100 years of combined mining and exploration experience, Fathom believes in a continuing bright outlook for nickel and its increasing use in the manufacturing of batteries needed for energy storage in the high-growth renewable energy and EV industries. The company’s modern approach to exploration has yielded significant new nickel discoveries.

Fathom is headquartered in Calgary, Alberta.

Projects

The Albert Lake Project

The Albert Lake Project comprises 90,460 hectares of lands located in north-central Saskatchewan, with over 80,000 hectares currently unexplored. The project is host to the historic Rottenstone Mine, a high-grade, open pit nickel sulfide past producer that was active from 1965 to 1969 and yielded ~26,000 tonnes of 3.3% Ni, 1.8% Cu, and >9 g/t Pd-Pt+Au.

The geological setting of the Albert Lake Project is within the Trans Hudson Orogeny (Corridor), which is host to numerous world-class nickel mining camps including the Thompson Nickel Belt (currently operating with more than 5 billion pounds of nickel produced since 1959), Lynn Lake (past producer) and Raglan Nickel Belt (currently operating with more than 39,000 tons of nickel produced in 2020).

The project is fully permitted. Exploration plans for 2024 include drilling a high-priority target located approximately 2km south of the historic Rottenstone Mine along with drilling other high-priority targets. Additional soil geochemistry, surface geophysical programs and geological mapping and prospecting will be performed during the summer field season.

The Gochager Lake Project

The Gochager Lake Project in northern Saskatchewan, also in the prolific Trans Hudson Corridor, was recently expanded through the addition of the contiguous Watt’s Lake property and direct staking, bringing its total land area to 22,620 hectares.

The Gochager Lake property is host to a historic resource defined by drilling in 1966-1967 consisting of 4.2 M tons grading 0.29% Ni and 0.08% Cu. Recent drilling by Fathom has defined multiple very robust off-hole borehole electromagnetic (BHEM) responses in eight of nine holes drilled in 2023 and three historic drill holes probed. There is very strong evidence of multiple, high-grade nickel-copper-cobalt steeply oriented chutes within the historic Gochager Lake Deposit.

Prior to Fathom exploration in 2023 and since 1970, exploration at the property has been limited to small drill programs in 1989-1990 and 2018. Exploration plans for 2024 include expanded surface geophysical programs, drilling and continued BHEM surveys to expand tons and increase the grade of the historic Gochager Lake deposit. Summer exploration will consist of soil geochemistry, mapping, prospecting and additional surface geophysical programs focused on identifying other Gochager-like deposits within the current land package.

Market Opportunity

Nickel plays a crucial role in clean energy technologies, and that is expected to cause demand to well outstrip supply for the foreseeable future.

With an annual market value of around $35 billion, nickel demand is projected to rise due to its intensive use in lithium-ion batteries used to power EVs. However, new discoveries of nickel sulfide deposits (currently the most reliable source for battery-grade class 1 nickel) have been rare, which could constrain class 1 nickel supply in the coming years.

According to Deloitte’s global EV forecast, total EV sales will grow from 2.5 million in 2020 to 11.2 million in 2025, reaching 31.1 million by 2030 and representing approximately 32% of the total market share for new car sales. Over the next 10 years, the EV market is projected to see a CAGR of 29%, with increased demand for nickel expected to be comparable.

Management Team

Fathom Nickel has assembled a best-in-class leadership team consisting of highly qualified industry professionals with deep knowledge and understanding of the mineral exploration industry and capital markets.

Ian Fraser, P.Geo., is CEO, VP Exploration and Co-Founder of Fathom Nickel. He has more than 35 years of experience in mineral exploration, as well as managing and implementing exploration projects in Canada and internationally. His experience includes resource interpretation and development of the Casa Berardi Gold Mine and Komis Gold Mine, as well as the Cisneros Gold Mine in Colombia.

Doug Porter, CPA, CA, CBV, is President, CFO and Director of Fathom Nickel. He is a senior financial and accounting executive with specific emphasis in resource company management. His career includes positions with Elan Coal Ltd., Altitude Resources Ltd. and StimWrx Oilfield Services Ltd.

Fathom Nickel Inc. (OTCQB: FNICF), closed Tuesday's trading session at $0.12, up 18.6944%, on 458,484 volume. The average volume for the last 3 months is 107,635 and the stock's 52-week low/high is $0.0449/$0.2634.

Recent News

• Fathom Nickel Inc. (CSE: FNI) (FSE: 6Q5) (OTCQB: FNICF) - Fathom Nickel sees multiple intercepts following successful drill program at Gochager Lake
• Fathom Nickel provides preliminary update on recent Gochager Lake drilling
• Fathom Announces Completion of 2,000+ Meter Drill Program at the Gochager Lake Property and the Completion of the First Anniversary Payments Under the Original Gochager Lake Earn-In Agreement

D-Wave Quantum Inc. (NYSE: QBTS)

The QualityStocks Daily Newsletter would like to spotlight D-Wave Quantum Inc. (NYSE: QBTS).

D-Wave Quantum Inc. (NYSE: QBTS) is a leader in quantum computing systems, software and services focused on delivering customer value via practical quantum applications for problems such as logistics, artificial intelligence, materials sciences, drug discovery, scheduling, fault detection and financial modeling. As the only provider building both annealing and gate-model quantum computers, the company is unlocking commercial use cases in optimization today, while building the technologies that will enable new solutions tomorrow.

D-Wave is a pioneer in quantum computing, with a history of delivering the world’s first commercial quantum computer; the first real-time quantum cloud service; countless hardware and software product and research milestones; and the planned first cross-platform quantum solution which will deliver both annealing and gate-model quantum computers to customers via an integrated platform. Its current commercial product offerings include: Advantage™ (fifth generation quantum computer), Leap™ (quantum cloud service), Launch™ (quantum computing onboarding service) and Ocean™ (full suite of open-source programming tools).

D-Wave’s relentless pursuit of practical quantum computing has resulted in the technology being used today by some of the world’s most advanced enterprises – more than 25 of the Forbes Global 2000 use D-Wave.

D-Wave’s commercial customers include blue-chip industry leaders like Volkswagen, Accenture, BBVA, NEC Corporation, Save-On-Foods, DENSO and Lockheed Martin. The company boasts an extensive IP portfolio featuring more than 200 issued U.S. patents and over 100 peer-reviewed papers published in leading scientific journals.

Founded in 1999, D-Wave is the world’s first commercial supplier of quantum computers. With headquarters and the Quantum Engineering Center of Excellence based near Vancouver, Canada, D-Wave’s U.S. operations are based in Palo Alto, California.

Advantage™ Quantum Computer

 

With the Advantage™ Quantum Computer, D-Wave has incorporated two decades of experience and over 10 years of customer feedback to create the first and only quantum computer designed for business. The platform features a new processor architecture with over 5,000 qubits and 15-way qubit connectivity. This is 2.5x more connections and more than double the number of qubits than the company’s previous generation quantum computer.

D-Wave’s quantum computers, first located in its facilities in British Columbia, have been available to North American users through its Leap™ quantum cloud service since 2018. It has since introduced new Advantage systems in Julich, Germany, and most recently, Marina Del Rey, California, which marked the availability of the first Advantage quantum computer physically located in the United States.

That new deployment is part of the USC-Lockheed Martin Quantum Computing Center (QCC) hosted at USC’s Information Sciences Institute (ISI), a unit of the University of Southern California’s prestigious Viterbi School of Engineering. Additionally, Amazon Web Services (AWS) and D-Wave announced that the U.S.-based system is available for use in Amazon 2racket, expanding the number to three different D-Wave quantum systems available to AWS users.

Leap Quantum Cloud Service

 

D-Wave’s customers interface with its systems through the Leap™ quantum cloud service. Leap delivers immediate, real-time access to the company’s Advantage quantum computer and quantum hybrid solver service, all with enterprise-class performance and scalability.

Leap allows developers proficient in Python to get started building and running quantum applications. Through a seamless and secure cloud-based connection, users can easily start solving complex problems of up to 1 million variables and 100,000 constraints.

Using Leap, D-Wave customers have developed quantum hybrid applications for use cases in manufacturing, logistics, financial services, life sciences, materials science, retail and transportation. By eliminating the need to wait hours, days or weeks to get good answers to a broad array of problems, D-Wave is helping businesses move forward.

D-Wave Launch

D-Wave Launch™ is the company’s onboarding platform aimed at helping businesses easily start their quantum journey. Through this program, D-Wave’s team of experts and partners aid enterprises in identifying best use cases for quantum and work with them to develop a proof of concept and production pilot.

From there, the team coordinates with customers to get their hybrid quantum applications up and running, providing ongoing Leap quantum cloud access to ensure the application is operating smoothly and delivering real business value.

Target Verticals

While the potential applications for quantum computing are effectively limitless, D-Wave has identified a number of industry verticals as key areas of focus for its quantum architecture, providing case studies for each. These include:

• Manufacturing – D-Wave worked with Volkswagen to identify a commercial optimization application, the binary paint shop problem, which was run on D-Wave’s hybrid solver service. The solver outperformed four purely classical methods on problem sizes at commercial scale (N=3,000). In a separate project, similar inputs were tested using a leading ion trap system, which failed to find any commercial solution.
• Life Sciences – Menten AI makes use of D-Wave quantum computing to assist in the design of novel therapeutic peptides—short strings of amino acids that can act as potent drugs. With the rise of COVID-19, D-Wave’s Advantage system made it possible to identify molecules that might be especially well-suited for binding and inhibiting the related spike protein, producing several promising peptide designs.
• Finance – Multiverse Computing, a leader in developing quantum solutions for the financial sector, leveraged D-Wave’s hybrid solver service in a collaboration with BBVA, one of the world’s largest financial institutions. Multiverse demonstrated management strategies that far exceeded the granularity of traditional returns in a fraction of the time, helping BBVA identify a low-risk portfolio for investment.

Market Opportunity

The quantum computing total addressable market is projected to grow between $450 billion and $850 billion over the next 15 to 30 years, with between $5 billion and $10 billion of anticipated TAM growth coming in the next three to five years, according to Boston Consulting Group. Driving factors behind this growth include rising investments in quantum computing tech by governments and an increasing number of commercial use-cases.

Forward-thinking organizations see quantum as an opportunity to move ahead of the competition. From finding efficiencies and reducing waste to decreasing time to solution and solving problems abandoned due to complexity, the business value is real. According to data from 451 Research, 40% of large enterprises are already experimenting with quantum computing.

D-Wave is strategically positioned – in an industry with significant barriers to entry – as evident by a decades-long track record serving a roster of blue-chip customers. The company is singularly focused on helping its customers achieve clear value by leveraging quantum computing in practical business applications. With a full stack of systems, software, developer tools and services, D-Wave is working to enable enterprises, governments, developers and researchers to access the power of quantum computing, thereby providing an intriguing opportunity for prospective investors.

D-Wave’s current investor base includes PSP Investments, Goldman Sachs, BDC Capital, NEC Corporation, Aegis Group Partners and In-Q-Tel.

Leadership Team

Dr. Alan Baratz has served as the CEO of D-Wave since 2020. Previously, as Executive Vice President of R&D and Chief Product Officer, he drove the development, delivery, and support of all of D-Wave’s products, technologies, and applications. Dr. Baratz has over 25 years of experience in product development and bringing new products to market at leading technology companies and software startups. As the first president of JavaSoft at Sun Microsystems, he oversaw the growth and adoption of the Java platform from its infancy to a robust platform supporting mission-critical applications in nearly 80 percent of Fortune 1000 companies. He has also held executive positions at Symphony, Avaya, Cisco, and IBM. Dr. Baratz holds a doctorate in computer science from the Massachusetts Institute of Technology.

John Markovich is the company’s CFO. He brings to D-Wave over three decades of experience working with rapidly growing private and public technology companies across all stages of development. Mr. Markovich has directed the finance, accounting, tax, treasury, M&A, legal, operations, customer service, IR, HR, and IT functions for companies ranging from privately held pre-revenue startups to an NYSE-listed Fortune 500 multi-national company with over $1.2 billion in annual revenue. During his career, he has negotiated and closed over 150 debt, equity, M&A, and joint venture transactions exceeding $2.5 billion in value; over a dozen private placements; nearly a dozen M&A transactions; and several international joint ventures. Mr. Markovich holds a BS in Business from Miami University and an MBA from the Michigan State Graduate School of Business.

D-Wave Quantum Inc. (NYSE: QBTS), closed Tuesday's trading session at $0.957, up 8.3928%, on 1,202,790 volume. The average volume for the last 3 months is 1.504M and the stock's 52-week low/high is $0.3962/$3.2.

Recent News

• D-Wave Quantum Inc. (NYSE: QBTS) - D-Wave Quantum Inc. (NYSE: QBTS) Adds Kirstjen Nielsen, Former Secretary of the U.S. Department of Homeland Security, to the Company's Board of Directors
• D-Wave Quantum Inc. (NYSE: QBTS) Announces Successful Completion of SOC 2 Type 2 Audit to Further Commitment to Data Security
• InvestorNewsBreaks - D-Wave Announces 1,200+ Qubit Advantage2(TM) Prototype, Strategic Collaboration with Deloitte Canada